Strategy of the Pharmaceutical Security Institute

Strategy

During the PSI General Assembly Meeting held March 2002, the worldwide problem of counterfeit drugs, which poses danger to the health and welfare of all people, was recognized and a new anti-counterfeiting strategy was approved. This strategy was designed to provide routine, high-quality intelligence products and improved communications to assist members’ anti-counterfeiting efforts. It is expected that the strategy will result in an improved, more effective anti-counterfeiting capability.

Key Elements

Development of incident reporting
Enhanced analytical assessments
Prompt dissemination of information about reported counterfeiting activities

One particular element critical to the success of the anti-counterfeiting strategy, is the need to build working partnerships. The pharmaceutical industry cannot stand alone against international counterfeiting groups engaged in clandestine, criminal operations. However, in concert with law enforcement, health care authorities and the customs services, a united front in opposition to counterfeiters will emerge.

PSI participates in a wide range of forums and activities which support anti-counterfeiting efforts. From training seminars to case specific information exchanges, PSI is committed to doing its share to guarantee the distribution of pharmaceuticals which are safe, effective and ultimately benefit all people.

Legal Statement